Organization | Vaxart

Vaxart Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: San Francisco California United States (2004)

Organization Overview

First Clinical Trial

2011

NCT01335347

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Vaxart | Vaxart, Inc.

Active Ingredients

Drugs in Phase 4 Trials (3)

Key: Vaxart (0) Acquired (3)

atorvastatin (lipitor) (1 trial)

calcium (2 trials)

sevelamer (renagel) (1 trial)

Drugs in Phase 3 Trials (3)

Key: Vaxart (0) Acquired (3)

nicvax (8 trials)

s. aureus type 5 & 8 capsular polysaccharide conjugate (6 trials)

staph aureus types 5 and 8 conjugate vaccine (1 trial)

Drugs in Phase 2 Trials (18)

Key: Vaxart (7) Acquired (11)

ap611074 (2 trials)

bivalent gii.4/gi.1 (1 trial)

bivalent rluks-pv / rat (1 trial)

Enzaplatovir (3 trials)

gi.1/gii.4 bivalent vlp vaccine (1 trial)

i-123-5-ia85380 (1 trial)

inactivated influenza vaccine (1 trial)

laninamivir octanoate hydrate (6 trials)

nicotine (nicorette) (2 trials)

s. aureus immune globulin (1 trial)

sodium chloride (1 trial)

staphylococcus aureus immune globulin (1 trial)

staphylococcus aureus toxoids (1 trial)

vapendavir (6 trials)

varenicline (chantix) (1 trial)

vxa-a1.1 (6 trials)

vxa-cov2-1 (2 trials)

vxa-g1.1-nn (5 trials)

Drugs in Phase 1 Trials (8)

Key: Vaxart (4) Acquired (4)

anti-hiv immune serum globulin (human) (1 trial)

bta9881 (1 trial)

cryptosporidium immune whey protein concentrate (1 trial)

midazolam (versed) (1 trial)

nd1.1 (2 trials)

vxa-byw.10 (1 trial)

vxa-g2.4-ns (1 trial)

vxa-rsv-f oral vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Caliciviridae Infections (Phase 1)

Gastroenteritis (Phase 1)

Influenza, Human (Phase 2)

Influenza in Birds (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 59
# of Trial APIs: 32